Laakmann G, Schule C, Baghai T, et al. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy.
Pharmacopsychiatry
. 1998;31(suppl):54 - 59.
Linde K, Ramirez G, Mulrow CD, et al. St. John's wort for depression - an overview and meta-analysis of randomised clinical trials.
BMJ
. 1996;313:253 - 258.
Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks.
BMJ.
1999;319:1534 - 1539.
Schrader E, Meier B, Brattstrom A. Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multicentre study.
Hum Psychopharmacol.
1998;13:163 - 169.
Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St. John's wort in major depression: a randomized controlled trial.
JAMA
. 2001;285:1978 - 1986.
Kalb R, Trautmann-Sponsel RD, Kieser M. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial.
Pharmacopsychiatry
. 2001;34:96 - 103.
Harrer G, Schmidt U, Kuhn U, et al. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine.
Arzneimittelforschung.
1999;49:289 - 296.
Schrader E. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild - moderate depression.
Int Clin Psychopharmacol.
2000;15:61 - 68.
Brenner R, Azbel V, Madhusoodanan S, et al. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study.
Clin Ther.
2000;22:411 - 419.
Suzuki O, Katsumata Y, Oya M, et al. Inhibition of monoamine oxidase by hypericin.
Planta Med
. 1984;50:272 - 274.
Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of hypericum extract.
J Geriatr Psychiatry Neurol.
1994;7(suppl 1):S57 - S59.
Thiede HM, Walper A. Inhibition of MAO and COMT by hypericum extracts and hypericin.
J Geriatr Psychiatry Neurol.
1994;7(suppl 1):S54 - S56.
Muller WE, Rossol R. Effects of hypericum extract on the expression of serotonin receptors
. J Geriatr Psychiatry Neurol
. 1994;7(suppl 1):S63 - S64.
Muller WE, Kasper S, Volz HP, et al. Hypericum extract (LI160) as an herbal antidepressant.
Pharmacopsychiatry.
1997;30(suppl 2):71 - 134.
Laakmann G, Schule C, Baghai T, et al. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy.
Pharmacopsychiatry
. 1998;31(suppl):54 - 59.
Heller B. Pharmacological and clinical effects of D-phenylalanine in depression and Parkinson's disease. In: Mosnaim AD, Wolf ME, eds.
Noncatecholic Phenylethylamines
, Part 1. New York, NY: Marcel Dekker; 1978:397 - 417.
Beckmann H, Athen D, Olteanu M, et al. DL-phenylalanine versus imipramine: a double-blind controlled study.
Arch Psychiatr Nervenkr.
1979;227:49 - 58.
Beckmann H. Phenylalanine in affective disorders.
Adv Biol Psychiatry
. 1983;10:137 - 147.
Byerley WF, Judd LL, Reimherr FW, et al. 5-hydroxytryptophan: a review of its antidepressant efficacy and adverse effects.
J Clin Psychopharmacol
. 1987;7:127 - 137.
Poldinger W, Calanchini B, Schwarz W. A functional-dimensional approach to depression: Serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine.
Psychopathology.
1991;24:53 - 81.
Eckmann F. Cerebral insufficiency--treatment with Ginkgo-biloba extract. Time of onset of effect in a double-blind study with 60 inpatients [translated from German].
Fortschr Med
. 1990;108:557 - 560.
Schubert H, Halama P. Depressive episode primarily unresponsive to therapy in elderly patients: efficacy of
Ginkgo biloba
extract EGb 761 in combination with antidepressants [translated from German].
Geriatr Forsch
. 1993;3:45 - 53.
Huguet F, Drieu K, Piriou A. Decreased cerebral 5-HT
1A
receptors during ageing: reversal by
Ginkgo biloba
extract (EGv 761).
J Pharm Pharmacol
. 1994;46:316 - 318.
Maggioni M, Picotti GB, Bondiolotti GP, et al. Effects of phosphatidylserine therapy in geriatric patients with depressive disorders.
Acta Psychiatr Scand
. 1990;81:265 - 270.
Brambilla F, Maggioni M, Panerai AE, et al. Beta-endorphin concentration in peripheral blood mononuclear cells of elderly depressed patients - effects of phosphatidylserine therapy.
Neuropsychobiology.
1996;34:18 - 21.
Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies.
Acta Neurol Scand Suppl
. 1994;154:7 - 14.
Echols JC, Naidoo U, Salzman C. SAMe (S-adenosylmethionine).
Harv Rev Psychiatry
. 2000;8:84 - 90.
Delle Chiaie R, Pancheri P. Combined analysis of two controlled, multicentric, double blind studies to assess efficacy and safety of Sulfo-Adenosyl-Methionine (SAMe) vs. placebo (MC1) and SAMe vs. clomipramine (MC2) in the treatment of major depression [in Italian; English abstract].
G Ital Psicopatol
. 1999;5:1 - 16.
Delle Chiaie R, Pancheri P, Scapicchio P. MC3: multicentre, controlled efficacy and safety trial of oral S-adenosyl-methionine (SAMe) vs. oral imipramine in the treatment of depression [abstract].
Int J Neuropsychopharmcol
. 2000;3(suppl 1):S230.
Bell KM, Plon L, Bunney WE Jr, et al. S-adenosylmethionine treatment of depression: a controlled clinical trial.
Am J Psychiatry
. 1988;145:1110-1114.
De Vanna M, Rigamonti R. Oral S-adenosyl-L-methionine in depression.
Curr Ther Res
. 1992;52:478 - 485.
Bell KM, Potkin SG, Carreon D, et al. S-adenosylmethionine blood levels in major depression: changes with drug treatment.
Acta Neurol Scand Suppl
. 1994;154:15 - 18.
Echols JC, Naidoo U, Salzman C. SAMe (S-adenosylmethionine).
Harv Rev Psychiatry
. 2000;8:84 - 90.
Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies.
Acta Neurol Scand Suppl
. 1994;154:7 - 14.
Delle Chiaie R, Pancheri P, Scapicchio P. MC4: multicentre, controlled efficacy and safety trial of intramuscular S-adenosyl-methionine (SAMe)
vs.
oral imipramine I the treatment of depression [abstract].
Int J Neuropsychopharmcol.
2000;3(suppl 1):S230.
Alpert JE, Fava M. Nutrition and depression: the role of folate.
Nutr Rev
. 1997;55:145 - 149.
Passeri M, Cucinotta D, Abate G, et al. Oral 5'-methyltetrahydrofolic acid in senile organic mental disorders with depression: results of a double-blind multicenter study.
Aging (Milano)
. 1993;5:63 - 71.
Godfrey PS, Toone BK, Carney MW, et al. Enhancement of recovery from psychiatric illness by methylfolate.
Lancet
. 1990;336:392 - 395.
Heseker H, Kubler W, Pudel V, et al. Psychological disorders as early symptoms of a mild-to-moderate vitamin deficiency.
Ann N Y Acad Sci
. 1992;669:352 - 357.
Crellin R, Bottiglieri T, Reynolds EH. Folates and psychiatric disorders: Clinical potential.
Drugs
. 1993;45:623 - 636.
Botez MI. Folate deficiency and neurological disorders in adults.
Med Hypotheses
. 1976;2:135 - 140.
Coppen A, Swade C, Jones SA, et al. Depression and tetrahydrobiopterin: the folate connection.
J Affect Disord
. 1989;16:103 - 107.
Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial.
J Affect Disord
. 2000;60:121 - 130.
Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial.
J Affect Disord
. 2000;60:121 - 130.
Meyer T, Broocks A. Therapeutic impact of exercise on psychiatric diseases: guidelines for exercise testing and prescription.
Sports Med
. 2000;30:269 - 279.
Eich H, Agelink MW, Lehmann E, et al. Acupuncture in patients with minor depressive episodes and generalized anxiety. Results of an experimental study [in German; English abstract].
Fortschr Neurol Psychiatr
. 2000;68:137 - 144.
Pascual-Leone A, Rubio B, Pallardo F, et al. Rapid-rate transcranial magnetic stimulation of the left dorsolateral prefrontal cortex in drug-resistant depression.
Lancet
. 1996;348:233-237.
Klein E, Kreinin I, Chistyakov A, et al. Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression: a double-blind controlled study.
Arch Gen Psychiatry
. 1999;56:315 - 320.
George MS, Wassermann EM, Kimbrell TA, et al. Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial.
Am J Psychiatry
. 1997;154:1752 - 1756.
Berman RM, Narasimhan M, Sanacora, et al. A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression.
Biol Psychiatry
. 2000;47:332 - 337.
Padberg F, Zwanzger P, Thoma H, et al. Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS.
Psychiatry Res
. 1999;88:163 - 171.
Boutros NN, Gueorguieva R, Hoffman RE, et al. Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression.
Psychiatry Res
. 2002;113:245 - 254.
Nemets B, Mishory A, Levine J, et al. Inositol addition does not improve depression in SSRI treatment failures.
J Neural Transm.
1999;106:795 - 798.
Bella R, Biondi R, Raffaele R, et al. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders.
Int J Clin Pharmacol Res.
1990;10:355 - 360.
Garzya G, Corallo D, Fiore A, et al. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression.
Drugs Exp Clin Res
. 1990;16:101 - 106.
Bell IR, Edman JS, Morrow FD, et al. B complex vitamin patterns in geriatric and young adult inpatients with major depression.
J Am Geriatr Soc
. 1991;39:252 - 257.
Zucker DK, Livingston RL, Nakra R, et al. B
12
deficiency and psychiatric disorders: case report and literature review.
Biol Psychiatry
. 1981;16:197 - 205.
Janicak PG, Dowd SM, Martis B, et al. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial.
Biol Psychiatry
. 2002;51:659 - 667.
Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone.
Am J Psychiatry.
1999;156:646 - 649.
Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder.
Am J Psychiatry.
2002;159:477-479.
Garcia-Toro M, Mayol A, Arnillas H, et al. Modest adjunctive benefit with transcranial magnetic stimulation in medication-resistant depression.
J Affect Disord.
2001;64:271 - 275.
Grunhaus L, Dannon PN, Schreiber S, et al. Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder: an open study.
Biol Psychiatry
. 2000;47:314 - 324.
Hasey G. Transcranial magnetic stimulation in the treatment of mood disorder: a review and comparison with electroconvulsive therapy.
Can J Psychiatry.
2001;46:720-727.
Kirkcaldie MT, Pridmore SA, Pascual-Leone A. Transcranial magnetic stimulation as therapy for depression and other disorders.
Aust N Z J Psychiatry.
1997;31:264 - 272.
Manes F, Jorge R, Morcuende M, et al. A controlled study of repetitive transcranial magnetic stimulation as a treatment of depression in the elderly.
Int Psychogeriatr.
2001;13:225 - 231.
Pridmore S. Substitution of rapid transcranial magnetic stimulation treatments for electroconvulsive therapy treatments in a course of electroconvulsive therapy.
Depress Anxiety.
2000;12:118 - 123.
Szuba MP, O'Reardon JP, Rai AS, et al. Acute mood and thyroid stimulating hormone effects of transcranial magnetic stimulation in major depression.
Biol Psychiatry.
2001;50:22 - 27.
Teneback CC, Nahas Z, Speer AM, et al. Changes in prefrontal cortex and paralimbic activity in depression following two weeks of daily left prefrontal TMS.
J Neuropsychiatry Clin Neurosci.
1999;11:426 - 435.
Hypericum Depression Trial Study Group. Effect of
Hypericum perforatum
(St. John's Wort) in major depressive disorder: a randomized controlled trial.
JAMA.
2002;287:1807-1814.
Behnke K, JensenGS, Graubaum HJ, et al.
Hypericum perforatum
versus fluoxetine in thetreatment of mild to moderate depression.
Adv Ther.
2002;19:43-52.
van Gurp G, Meterissian GB, Haiek LN, et al. St John's wort or sertraline?Randomized controlled trial in primary care.
Can Fam Physician.
2002;48:905-912.
Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs.
Arch Gen Psychiatry.
2002;59:913-919.
Pancheri P, Scapicchio P, Chiaie RD. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
Int J Neuropsychopharmacol
. 2002;5:287 - 294.
Marangell LB, Martinez JM, Zboyan HA, et al. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression.
Am J Psychiatry
. 2003;160:996 - 998.
Akhondzadeh S, Kashani L, Fotouhi A, et al. Comparison of Lavandula angustifolia Mill tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized trial.
Prog Neuropsychopharmacol Biol Psychiatry
. 2003;27:123 - 127.
Davidson JR, Abraham K, Connor KM, et al. Effectiveness of chromium in atypical depression: a placebo-controlled trial.
Biol Psychiatry
. 2003;53:261 - 264.
Sharma K, Kushwaha H, Sharma, S. A placebo-controlled trial on the efficacy of Mentat in managing depressive disorders.
Probe
. 1993;33:26 - 31.
Janakiramaiah N, Gangadhar BN, Naga Venkatesh Murthy PJ, et al. Antidepressant efficacy of Sudarshan Kriya Yoga (SKY) in melancholia: a randomized comparison with electroconvulsive therapy (ECT) and imipramine.
J Affect Disord
. 2000;57:255 - 259.
Field T. Massage therapy. Med Clin North Am. 2002;86:163 - 171.134. Dolberg OT, Dannon PN, Schreiber S, et al. Transcranial magnetic stimulation in patients with bipolar depression: a double blind, controlled study.
Bipolar Disord
. 2002;4:94 - 95.
Último revisado Septiembre de 2003 por EBSCO CAM Medical Review Board
La información aquí suministrada complementa la atención recibida por su médico. De ninguna forma intenta sustituir el consejo de un professional medico. LLAME A SU MEDICO DE INMEDIATO SI PIENSA QUE PODRIA TENER UNA EMERGENCIA. Siempre busque consejo médico antes de comenzar un nuevo tratamiento o si tiene preguntas sobre una condición médica.
Copyright © EBSCO Publishing. All rights reserved.